Last reviewed · How we verify

Strategic Science & Technologies, LLC — Portfolio Competitive Intelligence Brief

Strategic Science & Technologies, LLC pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Oral Sildenafil 50 mg Oral Sildenafil 50 mg marketed
SST-0225 SST-0225 phase 3 SGLT2 inhibitor SGLT2 Diabetes
SST-0225 Topical Ibuprofen Cream SST-0225 Topical Ibuprofen Cream phase 3 NSAID Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Novartis · 2 shared drug classes
  2. Allergan · 2 shared drug classes
  3. Apsen Farmaceutica S.A. · 2 shared drug classes
  4. AstraZeneca · 2 shared drug classes
  5. Pfizer · 2 shared drug classes
  6. Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
  7. AceLink Therapeutics, Inc. · 1 shared drug class
  8. AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Strategic Science & Technologies, LLC:

Cite this brief

Drug Landscape (2026). Strategic Science & Technologies, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/strategic-science-technologies-llc. Accessed 2026-06-10.

Related